adplus-dvertising
Close Menu
Breaking News:
Subscribe
Health News Sonia UleborBy

FDA expands use of remdesivir to patients with high risk of hospitalization

FDA expands use of remdesivir to patients with high risk of hospitalization
FILE PHOTO: An ampule of Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS

The U.S. health regulator on Friday expanded its approval for the use of Gilead Sciences’ antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate COVID-19 disease with high risk of hospitalization.

Previously, the use of Veklury was limited to patients requiring hospitalization.

 

(Reporting by Leroy Leo in Bengaluru; editing by Diane Craft)

Share.

Related Posts